Getting TRAIL back on track for cancer therapy

@inproceedings{Lemke2014GettingTB,
  title={Getting TRAIL back on track for cancer therapy},
  author={Johannes Lemke and Silvia von Karstedt and Julia Zinngrebe and Henning Walczak},
  booktitle={Cell Death and Differentiation},
  year={2014}
}
Unlike other members of the TNF superfamily, the TNF-related apoptosis-inducing ligand (TRAIL, also known as Apo2L) possesses the unique capacity to induce apoptosis selectively in cancer cells in vitro and in vivo. This exciting discovery provided the basis for the development of TRAIL-receptor agonists (TRAs), which have demonstrated robust anticancer activity in a number of preclinical studies. Subsequently initiated clinical trials testing TRAs demonstrated, on the one hand, broad… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 113 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 173 references

Similar Papers

Loading similar papers…